Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites

NCT01852409 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Refractory Malignant Ascites

Interventions

DRUG: bevacizumab

Sponsor

Peking University